Quick Answer
Arcutis Biotherapeutics, Inc. reported R&D Expense of $77.05 million for fiscal year 2025.
Arcutis Biotherapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $77.05M | +0.8% |
| 2024 | $76.42M | -30.9% |
| 2023 | $110.58M | -39.4% |
| 2022 | $182.44M | +25.3% |
| 2021 | $145.56M | +26.2% |
| 2020 | $115.31M | +215.7% |
| 2019 | $36.52M | +103.6% |
| 2018 | $17.94M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.60M | +0.5% | +0.8% |
| June 30, 2025 | $19.45M | +0.8% | +10.9% |
| March 31, 2025 | $17.54M | -24.2% | -10.0% |
| September 30, 2024 | $19.50M | -25.7% | +1.1% |
| June 30, 2024 | $19.30M | -23.5% | -16.6% |
| March 31, 2024 | $23.14M | -34.5% | -11.8% |
| September 30, 2023 | $26.24M | -62.4% | +4.0% |
| June 30, 2023 | $25.22M | -34.0% | -28.6% |
- Arcutis Biotherapeutics, Inc. showed an increase of +0.8% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Arcutis Biotherapeutics, Inc.’s r&d expense has grown by 329.5% (from $17.94 million to $77.05 million).
- The most recent figure is from Arcutis Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: